105 related articles for article (PubMed ID: 7564499)
1. CD30 expression in normal and neoplastic lymphoid tissue: biological aspects and clinical implications.
de Bruin PC; Gruss HJ; van der Valk P; Willemze R; Meijer CJ
Leukemia; 1995 Oct; 9(10):1620-7. PubMed ID: 7564499
[TBL] [Abstract][Full Text] [Related]
2. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
3. CD30: expression and function in health and disease.
Horie R; Watanabe T
Semin Immunol; 1998 Dec; 10(6):457-70. PubMed ID: 9826579
[TBL] [Abstract][Full Text] [Related]
4. Neuron-specific enolase (gamma enolase, gamma-gamma dimer) expression in Hodgkin's disease and large cell lymphomas.
Massarelli G; Onida GA; Piras MA; Marras V; Mura A; Tanda F
Anticancer Res; 1999; 19(5B):3933-8. PubMed ID: 10628334
[TBL] [Abstract][Full Text] [Related]
5. Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype.
Kummer JA; Vermeer MH; Dukers D; Meijer CJ; Willemze R
J Invest Dermatol; 1997 Nov; 109(5):636-40. PubMed ID: 9347791
[TBL] [Abstract][Full Text] [Related]
6. c-Jun expression and activation are restricted to CD30+ lymphoproliferative disorders.
Drakos E; Leventaki V; Schlette EJ; Jones D; Lin P; Medeiros LJ; Rassidakis GZ
Am J Surg Pathol; 2007 Mar; 31(3):447-53. PubMed ID: 17325487
[TBL] [Abstract][Full Text] [Related]
7. Classification of primary cutaneous large cell lymphomas.
Willemze R; Beljaards RC; Rijlaarsdam U
Dermatol Clin; 1994 Apr; 12(2):361-73. PubMed ID: 8045048
[TBL] [Abstract][Full Text] [Related]
8. mRNA expression patterns indicate CD30 mediated activation of different apoptosis pathways in anaplastic large cell lymphoma but not in Hodgkin's lymphoma.
Staber PB; Noehammer C; Dürkop H; Schauer S; Kenner L; Linkesch W; Hoefler G
Leuk Res; 2006 Mar; 30(3):343-8. PubMed ID: 16198418
[TBL] [Abstract][Full Text] [Related]
9. Expression and regulation of CD30 ligand and CD30 in human leukemia-lymphoma cell lines.
Gruss HJ; DaSilva N; Hu ZB; Uphoff CC; Goodwin RG; Drexler HG
Leukemia; 1994 Dec; 8(12):2083-94. PubMed ID: 7528856
[TBL] [Abstract][Full Text] [Related]
10. Sinusoidal CD30-positive large B-cell lymphoma: a morphologic mimic of anaplastic large cell lymphoma.
Lai R; Medeiros LJ; Dabbagh L; Formenti KS; Coupland RW
Mod Pathol; 2000 Mar; 13(3):223-8. PubMed ID: 10757332
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease.
Kanavaros P; Vlychou M; Stefanaki K; Rontogianni D; Gaulard P; Pantelidaki E; Zois M; Darivianaki K; Georgoulias V; Boulland ML; Gorgoulis V; Kittas C
Anticancer Res; 1999; 19(2A):1209-16. PubMed ID: 10368677
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of CD30 (Ki-1/Ber-H2) expression in primary cutaneous large-cell lymphomas of T-cell origin. A clinicopathologic and immunohistochemical study in 20 patients.
Beljaards RC; Meijer CJ; Scheffer E; Toonstra J; van Vloten WA; van der Putte SC; Geerts ML; Willemze R
Am J Pathol; 1989 Dec; 135(6):1169-78. PubMed ID: 2556926
[TBL] [Abstract][Full Text] [Related]
13. Expression and function of CD30 on T lymphocytes.
Tarkowski M
Arch Immunol Ther Exp (Warsz); 1999; 47(4):217-21. PubMed ID: 10483869
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of thymus and activation regulated chemokine and its receptor CCR4 in nodal and cutaneous anaplastic large-cell lymphomas and Hodgkin's disease.
Vermeer MH; Dukers DF; ten Berge RL; Bloemena E; Wu L; Vos W; de Vries E; Tensen CP; Meijer CJ; Willemze R
Mod Pathol; 2002 Aug; 15(8):838-44. PubMed ID: 12181269
[TBL] [Abstract][Full Text] [Related]
15. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
16. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation.
Dürkop H; Hirsch B; Hahn C; Foss HD; Stein H
J Pathol; 2003 Jun; 200(2):229-39. PubMed ID: 12754742
[TBL] [Abstract][Full Text] [Related]
17. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma with a CD15(+)CD30(-) phenotype.
Yoshizawa N; Yagi H; Horibe T; Takigawa M; Sugiura M
Eur J Dermatol; 2007; 17(5):441-2. PubMed ID: 17673391
[TBL] [Abstract][Full Text] [Related]
18. Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project.
Weisenburger DD; Anderson JR; Diebold J; Gascoyne RD; MacLennan KA; Müller-Hermelink HK; Nathwani BN; Ullrich F; Armitage JO
Am J Hematol; 2001 Jul; 67(3):172-8. PubMed ID: 11391714
[TBL] [Abstract][Full Text] [Related]
19. CD30 expression in non-Hodgkin's lymphoma.
Piris M; Brown DC; Gatter KC; Mason DY
Histopathology; 1990 Sep; 17(3):211-8. PubMed ID: 2173674
[TBL] [Abstract][Full Text] [Related]
20. Nodular lymphocyte predominant Hodgkin's disease and anaplastic large-cell (CD30+) lymphoma: distinct entities or nonspecific patterns?
Menestrina F; Chilosi M; Scarpa A
Semin Diagn Pathol; 1995 Aug; 12(3):256-69. PubMed ID: 8545592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
